Direction of new drug research:soft regulation of inflammatory immune responses
2017-01-16 03:42WeiWEI
中國(guó)藥理學(xué)與毒理學(xué)雜志 2017年10期
Wei WEI
(Institute of Clinical Pharmacology,Anhui Medical University,Key Laboratory of Anti-inflammatory and Immune Medicine,Ministry of Education,Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine,Hefei 230032,China）
中國(guó)藥理學(xué)與毒理學(xué)雜志2017年10期
- 中國(guó)藥理學(xué)與毒理學(xué)雜志的其它文章
- Pharmacological study on traditional Chinese medicine and natural product in China
- GPCRomics:tissue and cellular GPCR expression identifies new therapeutic targets
- Targeting Gprotein-coupled receptors for the treatment of autoimmune diseases
- Arrestin mediated GPCR biased signaling and its application in new drug discovery
- Identification of a novel target for cancer and anti-fibrotic therapy
- Rational design of GRK2 inhibitors for the treatment of heart failure